Zacks Investment Research downgraded Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to Hold in a report released today.
- Updated: November 28, 2016
Zacks Investment Research has downgraded Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to Hold in a report released on 11/28/2016.
Previously on 11/25/2016, Zacks Investment Research reported about Conatus Pharmaceuticals Inc (NASDAQ:CNAT) raised the target price from $0.00 to $2.00. At the time, this indicated a possible upside of 0.06%.
Yesterday Conatus Pharmaceuticals Inc (NASDAQ:CNAT) traded -1.55% lower at $1.93. CNAT’s 50-day average is $1.86 and its two hundred day average is $2.03. With the last stock price close down -6.23% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Trading volume was down over the average, with 42,992 shares of CNAT changing hands under the typical 562,661
Recent Performance Chart
Conatus Pharmaceuticals Inc has with a one year low of $1.40 and a one year high of $4.05 and has a market capitalization of $0.
General Company Details For Conatus Pharmaceuticals Inc (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.